ShareValue scores for BROOKS.NSE: Valuation 79, Quality 46, Growth 23, Health 58.

BROOKS.NSE
NSE

Brooks Laboratories Limited

₹60.95(+1.09%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

13% to 28%
Valuation
79
Undervalued
Price vs Value
Quality
46
Moderate
Business Strength
Growth
23
Weak
Revenue & Earnings
Health
58
Moderate
Financial Stability
Momentum
58
Neutral
Price Trend

Company Details

About

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026